Literature DB >> 11471343

Aspirin-induced asthma.

L T Vaszar1, D D Stevenson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11471343     DOI： 10.1385/CRIAI:21:1:71

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


× No keyword cloud information.
  76 in total

1.  Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.

Authors:  B Dahlén; E Nizankowska; A Szczeklik; O Zetterström; G Bochenek; M Kumlin; L Mastalerz; G Pinis; L J Swanson; T I Boodhoo; S Wright; L M Dubé; S E Dahlén
Journal:  Am J Respir Crit Care Med       Date:  1998-04       Impact factor: 21.405

2.  Intolerance to aspirin. Clinical studies and consideration of its pathogenesis.

Authors:  M Samter; R F Beers
Journal:  Ann Intern Med       Date:  1968-05       Impact factor: 25.391

3.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.

Authors:  K H In; K Asano; D Beier; J Grobholz; P W Finn; E K Silverman; E S Silverman; T Collins; A R Fischer; T P Keith; K Serino; S W Kim; G T De Sanctis; C Yandava; A Pillari; P Rubin; J Kemp; E Israel; W Busse; D Ledford; J J Murray; A Segal; D Tinkleman; J M Drazen
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

4.  Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma.

Authors:  S Yoshida; H Sakamoto; Y Ishizaki; K Onuma; T Shoji; H Nakagawa; H Hasegawa; M Nakabayashi; H Amayasu
Journal:  Clin Exp Allergy       Date:  2000-01       Impact factor: 5.018

5.  Effect of oral prednisone on airway inflammatory mediators in atopic asthma.

Authors:  R Dworski; G A Fitzgerald; J A Oates; J R Sheller
Journal:  Am J Respir Crit Care Med       Date:  1994-04       Impact factor: 21.405

6.  Bronchoprotective role for endogenous prostaglandin E2.

Authors:  I D Pavord; A E Tattersfield
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

7.  Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma.

Authors:  M E Wechsler; D Finn; D Gunawardena; R Westlake; A Barker; S P Haranath; R A Pauwels; J C Kips; J M Drazen
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

Review 8.  Commentary: the American experience with aspirin desensitization for aspirin-sensitive rhinosinusitis and asthma.

Authors:  D D Stevenson
Journal:  Allergy Proc       Date:  1992 Jul-Aug

9.  Aspirin-induced asthma and nasal polyps.

Authors:  S Ogino; T Harada; I Okawachi; M Irifune; T Matsunaga; T Nagano
Journal:  Acta Otolaryngol Suppl       Date:  1986

10.  Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.

Authors:  K Sladek; R Dworski; J Soja; J R Sheller; E Nizankowska; J A Oates; A Szczeklik
Journal:  Am J Respir Crit Care Med       Date:  1994-04       Impact factor: 21.405
View more
  3 in total

1.  National Athletic Trainers' Association position statement: management of asthma in athletes.

Authors:  Michael G Miller; John M Weiler; Robert Baker; James Collins; Gilbert D'Alonzo
Journal:  J Athl Train       Date:  2005 Jul-Sep       Impact factor: 2.860

2.  Studies on Shokyo, Kanzo, and Keihi in Kakkonto Medicine on Prostaglandin E2 Production in Lipopolysaccharide-Treated Human Gingival Fibroblasts.

Authors:  Toshiaki Ara; Norio Sogawa
Journal:  Int Sch Res Notices       Date:  2016-10-13

3.  Effects of shokyo (Zingiberis Rhizoma) and kankyo (Zingiberis Processum Rhizoma) on prostaglandin E2 production in lipopolysaccharide-treated mouse macrophage RAW264.7 cells.

Authors:  Toshiaki Ara; Masanori Koide; Hiroyuki Kitamura; Norio Sogawa
Journal:  PeerJ       Date:  2019-09-17       Impact factor: 2.984
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.